Graybug Vision, Inc.（纳斯达克股票代码：GRAY）认为空头利率将大幅下降

Graybug Vision, Inc. (NASDAQ:GRAY – Get Rating) was the target of a significant decline in short interest in February. As of February 15th, there was short interest totalling 24,400 shares, a decline of 39.3% from the January 31st total of 40,200 shares. Based on an average trading volume of 42,400 shares, the short-interest ratio is presently 0.6 days. Currently, 0.2% of the company's stock are short sold.

Hedge Funds Weigh In On Graybug Vision

A number of institutional investors and hedge funds have recently modified their holdings of GRAY. BML Capital Management LLC acquired a new position in shares of Graybug Vision during the fourth quarter worth $618,000. Renaissance Technologies LLC grew its stake in shares of Graybug Vision by 284.8% during the third quarter. Renaissance Technologies LLC now owns 200,492 shares of the company's stock worth $189,000 after purchasing an additional 148,392 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Graybug Vision during the first quarter worth $125,000. Finally, Vanguard Group Inc. grew its stake in shares of Graybug Vision by 5.5% during the first quarter. Vanguard Group Inc. now owns 455,572 shares of the company's stock worth $561,000 after purchasing an additional 23,846 shares in the last quarter. Institutional investors and hedge funds own 49.94% of the company's stock.

Graybug Vision Stock Performance

Shares of NASDAQ:GRAY traded up $0.03 during trading on Friday, hitting $0.58. The company's stock had a trading volume of 19,817 shares, compared to its average volume of 22,218. The business has a 50 day moving average price of $0.64 and a two-hundred day moving average price of $0.80. The company has a market capitalization of $12.54 million, a PE ratio of -0.34 and a beta of 1.20. Graybug Vision has a fifty-two week low of $0.45 and a fifty-two week high of $1.58.

About Graybug Vision

(Get Rating)

Graybug Vision, Inc, a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema.

Recommended Stories

• Get a free copy of the StockNews.com research report on Graybug Vision (GRAY)
• MarketBeat Week in Review – 2/27 – 3/3
• The 3 Most Upgraded Stocks Are Reversing
• How to Find Blue Chip Dividend Stocks
• Zscaler, Inc Plummets, Is It Time To Buy The Dip?
• What is a Good Dividend Yield? How to Decide

Receive News & Ratings for Graybug Vision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graybug Vision and related companies with MarketBeat.com's FREE daily email newsletter.